ArticleJournal of cancer research and clinical oncology2004
Overexpression of E2F1 associated with LOH at RB locus and hyperphosphorylation of RB in non-small cell lung carcinoma.
Article in Journal of cancer research and clinical oncology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Estimation of an Image Biomarker for Distant Recurrence Prediction in NSCLC Using Proliferation-Related Genes.International journal of molecular sciences · 2023Article
- Lung squamous cell carcinoma and lung adenocarcinoma differential gene expression regulation through pathways of Notch, Hedgehog, Wnt, and ErbB signalling.Scientific reports · 2020Article
- Differential expression of lung adenocarcinoma transcriptome with signature of tobacco exposure.Journal of applied genetics · 2020Article
- Harnessing Gene Expression Profiles for the Identification of Ex Vivo Drug Response Genes in Pediatric Acute Myeloid Leukemia.Cancers · 2020Article
- ANKRD22 promotes progression of non-small cell lung cancer through transcriptional up-regulation of E2F1.Scientific reports · 2017Article
- Interrupted E2F1-miR-34c-SCF negative feedback loop by hyper-methylation promotes colorectal cancer cell proliferation.Bioscience reports · 2015Article
- E2F8 as a Novel Therapeutic Target for Lung Cancer.Journal of the National Cancer Institute · 2015Article
- E2F2 induction in related to cell proliferation and poor prognosis in non-small cell lung carcinoma.International journal of clinical and experimental pathology · 2015Article
- Transcription addiction: can we garner the Yin and Yang functions of E2F1 for cancer therapy?Cell death & disease · 2014Review
- E2F activators signal and maintain centrosome amplification in breast cancer cells.Molecular and cellular biology · 2014Article
- E2F1 promotes angiogenesis through the VEGF-C/VEGFR-3 axis in a feedback loop for cooperative induction of PDGF-B.Journal of molecular cell biology · 2013Article
- E2F transcription factors and digestive system malignancies: how much do we know?World journal of gastroenterology · 2013Review
- Rbf1 degron dysfunction enhances cellular DNA replication.Cell cycle (Georgetown, Tex.) · 2012Article
- A network-based biomarker approach for molecular investigation and diagnosis of lung cancer.BMC medical genomics · 2011Article
- Emerging roles of E2Fs in cancer: an exit from cell cycle control.Nature reviews. Cancer · 2009Review
- Article
- γ-tubulin as a signal-transducing molecule and meshwork with therapeutic potential.Signal transduction and targeted therapyReview
- Role of cell cycle regulators in lung carcinogenesis.Cell adhesion & migrationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeE2F1 plays a critical role in cell proliferation, and its function is controlled by the retinoblastoma (RB) protein. We examined the expression of E2F1 and the aberration of RB gene and protein to elucidate what factors contribute to the overexpression of E2F1 in non-small cell lung carcinomas.
methodsThe expression level of E2F1 in tissues of non-small cell lung carcinomas was measured by means of quantitative reverse transcription-polymerase chain reaction and immunohistochemistry. For RB, we examined loss of heterozygosity (LOH) by PCR-restriction fragment length polymorphism and a variable number of tandem repeats, and protein expression by immunohistochemistry.
resultsFifteen cases of carcinoma (46%) showed high transcription levels of E2F1 gene. Immunohistochemically, almost all (14 of 15) cases overexpressing E2F1 mRNA were positive for E2F1 protein. LOH at the RB locus was found in 13 of 30 informative cases. In 13 cases with LOH, ten showed overexpression of E2F1 mRNA and protein. Immunohistochemical positivity for phosphorylated RB protein was also closely correlated with overexpression of E2F1.
conclusionsOur results suggest that overexpression of E2F1, induced both by LOH at the RB locus and anomalous phosphorylation of the RB protein, is involved in the development of non-small cell lung carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.